source
- Seven deaths linked to Neurocrine’s Prader-Willi drug Vykat raise safety concernsClinicians have warned that seven patients who received Neurocrine Biosciences' recently approved Prader-Willi syndrome therapy Vykat have died, prompting a new safety alert for the patient communi…
- Sentynl inks up to $475M licensing deal to commercialize Mereo’s alvelestat for rare lung diseaseSentynl Therapeutics, a subsidiary of Zydus Lifesciences, signed an agreement to obtain exclusive U.S. rights to market alvelestat, Mereo BioPharma’s investigational therapy for alpha-1 antitrypsin…